全国服务咨询热线：
18438616290
18438616290
产品分类
Product Category详细介绍
| 品牌 | absin | CAS | 82586-52-5 |
|---|---|---|---|
| 分子式 | C27H34N2O7.HCl | 纯度 | 98% |
| 分子量 | 535.03 | 货号 | abs47028317 |
| 规格 | 10mg | 供货周期 | 现货 |
| 主要用途 | used for the treatment of hypertension | 应用领域 | 化工,生物产业,农林牧渔,制药/生物制药,综合 |
Moexipril hydrochloride 82586-52-5
| 产品描述 | |
| 描述 | Moexipril HCl is a potent orally active nonsulfhydrylangiotensin converting enzyme (ACE)inhibitor, used for the treatment of hypertension and congestive heart failure. |
| 纯度 | 98% |
| 储存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 别名 | 盐酸莫西普利；莫昔普利盐酸盐；RS-10085 |
| 外观 | 白色粉末 |
| 可溶性/溶解性 | DMSO : 53.5 mg/mL (100 mM) water : 53.5 mg/mL (100 mM) |
| 生物活性 | |
| 靶点 | ACE |
| In vitro(体外研究) | Moexipril dose-dependently reduces the percentage of damaged neurons, as well as mitochondrial reactive oxygen species generation induced by glutamate, staurosporine or Fe2+/3+. Moexipril and enalapril attenuates staurosporine-induced neuronal apoptosis as determined by nuclear staining with Hoechst 33258. |
| In vivo(体内研究) | Moexipril (0.3 mg/kg) significantly reduces brain damage after focal ischemia as compared to control mice. Moexipril (0.01 mg/kg) is able to reduce the infarct volume in the rat model after focal cerebral ischemia. Moexipril reduces blood pressure after the first week of treatment but it has no apparent effect on either the proximal tibial metaphysis or the tibial shaft in ovariectomized (OVX) spontaneously hypertensive rats (SHR). Moexipril combined with hydrochlorothiazide (HCTZ) exhibits a much more potent hypotensive effect and has the same effect on bone mass and dynamic end-points as HCTZ alone. Moexiprilat exhibits a higher inhibitory potency than enalaprilat against both plasma ACE and purified ACE from rabbit lung. Moexipril (0.1-30 mg/kg/day) lowers blood pressure and differentially inhibits ACE activity in plasma, lung, aorta, heart and kidney in a dose-dependent fashion. Moexipril (10 mg/kg/day) leads to comparable decreases in blood pressure, inhibition of plasma ACE and reduction of plasma angiotensinogen and to a similar attenuation of the pressor responses to angiotensin I and potentiation of the depressor responses to bradykinin. |
| 参考文献 | |
| 参考文献 |
| 研究领域 | |
| 研究领域 | NeuroscienceEndocrine system Drug DiscoverySmall Molecule DrugLead Compound Discovery |
产品咨询
地址：上海市浦东新区新浩路58号申江科创园18栋
邮箱：lanwu@univ-bio.com
传真：